沈迎,张奇,张瑞岩,沈卫峰

• 1:上海交通大学医学院附属瑞金医院心脏科
• 2:同济大学医学院附属上海东方医院心内科

摘要(Abstract)：

<正>自2002年Cribier等~([1])在Circulation上发表首个病例报道以来，经导管主动脉瓣置换术（transcatheter aortic valve replacement,TAVR）已成为症状性、外科主动脉瓣置换术（surgical aortic valve replacement,SAVR）高危患者治疗的“金标准”~([2-3])。近年来的研究表明，TAVR也有望成为中、低危主动脉瓣病变患者一种实用的治疗选择~([4])。显然，由于退行性主动脉瓣病变（尤其是主动脉瓣狭窄）与冠状动脉疾病的发病机制和易患因素具有多方面相似性（例如糖尿病、高胆固醇血症、高血压），加上老龄化社会的形成，

关键词(KeyWords)： 经导管主动脉瓣置换术;主动脉瓣狭窄;冠状动脉疾病;血运重建

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 沈迎,张奇,张瑞岩,沈卫峰

参考文献(References)：

• [1]Cribier A,Eltchaninoff H,Bash A,et al.Percutaneous transcatheter implantation of an aortic valve prosthesis for calcific aortic stenosis:first human case description[J].Circulation,2002,106(24):3006-3008.DOI:10.1161/01.cir.0000047200.36165.b8.
• [2]Tugaoen Z,Nguyen P,Arora S,et al.The selection of transcatheter heart valves in transcatheter aortic valve replacement[J].Trends Cardiovasc Med,2022,32(8):513-522.DOI:10.1016/j.tcm.2021.10.002.
• [3] Boskovski MT,Gleason TG.Current therapeutic options in aortic stenosis[J].Circ Res,2021,128(9):1398-1417.DOI:10.1161/CIRCRESAHA.121.318040.
• [4] Leon MB,Mack MJ,Hahn RT,et al.Outcomes 2 years after transcatheter aortic valve replacement in patients at low surgical risk[J].J Am Coll Cardiol,2021,77(9):1149-1161.DOI:10.1016/j.jacc.2020.12.052.
• [5] Altibi AM,Ghanem F,Hammad F,et al.Clinical outcomes of revascularization with percutaneous coronary intervention prior to transcatheter aortic valve replacement:a comprehensive meta-analysis[J].Curr Probl Cardiol,2022,47(11):101339.DOI:10.1016/j.cprardiol.2022101339.
• [6] Guo Y,Zhang W,Wu H.Percutaneous versus surgical approach to aortic valve replacement with coronary revascularization:a systematic review and meta-analysis[J].Perfusion,2023,2676591231178894.DOI:10.1177/02676591231178894.
• [7] Alperi A,Mohammadi S,Campelo-Parada F,et al.Transcatheter versus surgical aortic valve replacement in patients with complex coronary artery disease[J].JACC Cardiovasc Interv,2021,14(22):2490-2499.DOI:10.1016/j.jcin.2021.08.073.
• [8]冯晔子,曹丰,李苏雷,等.主动脉瓣重度狭窄患者经皮导管主动脉瓣置换术的安全性和有效性分析[J].中国介入心脏病学杂志,2022,30(1):29-32.DOI:10.3969/j.issn.1004-8812.2022.01.005.
• [9]中国医师协会心血管内科医师分会结构性心脏病专业委员会.中国经导管主动脉瓣置换术临床路径专家共识(2021版)[J].中国介入心脏病学杂志,2022,30(1):7-16.DOI:10.3969/j.issn.1004-8812.2022.01.002.
• [10]范嘉祺,刘先宝,艾丽菲热·艾合买提,等.经导管主动脉瓣置换术围术期冠状动脉闭塞的评估和处理流程[J].中国介入心脏病学杂志,2023,31(6):461-466.DOI:10.3969/j.issn.1004-8812.2023.06.010.
• [11]张洪亮,刘庆荣,陈阳,等.经导管主动脉瓣置换术后行经皮冠状动脉介入治疗初步经验[J].中国介入心脏病学杂志,2023,31(6):427431.DOI:10.3969/j.issn.1004-8812.2023.06.004.
• [12]俞吉维,杜润,朱政斌,等.经导管主动脉瓣置换术患者冠状动脉疾病的管理与处理策略[J].中国介入心脏病学杂志,2023,31(6):452-456.DOI:10.3969/j.issn.1004-8812.2023.06.008.
• [13] Tarantini G,Tang G,Nai Fovino L,et al.Management of coronary artery disease in patients undergoing transcatheter aortic valve implantation.A clinical consensus statement from the European Association of Percutaneous Cardiovascular Interventions in collaboration with the ESC Working Group on Cardiovascular Surgery[J].EuroIntervention,2023,19(1):37-52.DOI:10.4244/EIJ-D-22-00958.
• [14]Lunardi M,Scarsini R,Venturi G,et al.Physiological versus angiographic guidance for myocardial revascularization in patients undergoing transcatheter aortic valve implantation[J].J Am Heart Assoc,2019,8:e012618.DOI:10.1161/JAHA.119.012618.
• [15]Auffret V,Ridard C,Salerno N,et al.Unmet needs in TAVR:conduction disturbances and management of coronary artery disease[J].J Clin Med,2022,11(21):6256.DOI:10.3390/jcm11216256.
• [16]Michail M,Ihdayhid AR,Comella A,et al.Feasibility and validity of computed tomography-derived fractional flow reserve in patients with severe aortic stenosis:the CAST-FFR study[J].Circ Cardiovasc Interv,2021,14(1):e009586.DOI:10.1161/CIRCINTERVENTIONS.120.009586.
• [17]Peper J,Becker LM,Van Den Berg H,et al.Diagnostic performance ofCCTA and CT-FFR for the detection of CAD in TAVR work-up[J].JACC Cardiovasc Interv,2022,15(11):1140-1149.DOI:10.1016/j.jcin.2022.03.025.
• [18]Minten L,Wissels P,McCutcheon K,et al.The effect of coronary lesion complexity and preprocedural revascularization on 5-year outcomes after TAVR[J].JACC Cardiovasc Interv,2022,15:1611-1620.DOI:10.1016/j.jcin.2022.06.019.
• [19]Patterson T,Clayton T,Dodd M,et al.ACTIVATION(percutaneous coronary intervention prior to transcatheter aortic valve implantation):a randomized clinical trial[J].JACC Cardiovasc Interv,2021,14:1965-1974.DOI:10.1016/j.jcin.2021.06.041.
• [20]Witberg G,Zusman O,Codner P,et al.Impact of coronary artery revascularization completeness on outcomes of patients with coronary artery disease undergoing transcatheter aortic valve replacement:a metaanalysis of studies using the residual SYNTAX Score(Synergy Between PCI With Taxus and Cardiac Surgery)[J].Circ Cardiovasc Interv,2018,11(3):e006000.DOI:10.1161/CIRCINTERVENTIONS.117.006000.
• [21]Stephan T,Thoma E,Rattka M,et al.Impact of extent of coronary artery disease and percutaneous revascularization assessed by the SYNTAX score on outcomes following transcatheter aortic valve replacement[J].BMC Cardiovasc Disord,2021,21(1):568.DOI:10.1186/s12872-021-02374-y.
• [22]Otto CM,Nishimura RA,Bonow RO,et al.2020 ACC/AHA guideline for the management of patients with valvular heart disease:executive summary:a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines[J].Circulation,2021,143:e35-e71.DOI:10.1161/CIR.0000000000000932.
• [23]Vahanian A,Beyersdorf F,Praz F,et al.2021 ESC/EACTS Guidelines for the management of valvular heart disease[J].Eur Heart J,2022,43:561-632.DOI:10.1093/eurheartj/ehab395.
• [24]Venturi G,Pighi M, Pesarini G,et al.Contrast-induced acute kidney injury in patients undergoing TAVI compared with coronary interventions[J].J Am Heart Assoc,2020,9:e017194.DOI:10.1161/JAHA.120.017194.
• [25]Yudi MB,Sharma SK,Tang GHL,et al.Coronary angiography and percutaneous coronary intervention after transcatheter aortic valve replacement[J].J Am Coll Cardiol,2018,71:1360-1378.DOI:10.1016/j.jacc.2018.01.057.
• [26]Tang GHL,Zaid S,Fuchs A,et al.Alignment of transcatheter aorticvalve neo-commissures(ALIGN TAVR):impact on final valve orientation and coronary artery overlap[J].JACC Cardiovasc Interv,2020,13:1030-1042.DOI:10.1016/j.jcin.2020.02.005.
• [27]Ochiai T,Chakravarty T,Yoon SH,et al.Coronary access after TAVR[J].JACC Cardiovasc Interv,2020,13:693-705.DOI:10.1016/j.jcin.2020.01.216.
• [28]Lindner JU,Sulimov DS,Thiele H,et al.Coronary intervention after valve-in-valve TAVR enabled by pre-TAVR BASILICA[J].JACC Cardiovasc Interv,2022,15(5):e49-e51.DOI:10.1016/j.jcin2022.01.010.
• [29]Dvir D,Leon MB,Abdel-Wahab M,et al.First-in-human dedicated leaflet splitting device for prevention of coronary obstruction in transcatheter aortic valve replacement[J].JACC Cardiovasc Interv,2023,16(1):94-102.DOI:10.1016/j.jcin.2022.10.050.
• [30]Ahmad Y,Howard JP,Madhavan MV,et al.Single versus dual antiplatelet therapy after transcatheter aortic valve replacement:a meta-analysis of randomized clinical trials[J].Cardiovasc Revasc Med,2022,34:46-53.DOI:10.1016/j.carrev.2021.01.016.
• [31]Genereux P,Pibarot P,Redfors B,et al.Evolution and prognostic impact of cardiac damage after aortic valve replacement[J].J Am Coll Cardiol,2022,80(8):783-800.DOI:10.1016/j.jacc.2022.05.006.
• [32]Arnold SV,Zhao Y,Leon MB,et al.Impact of frailty and prefrailty on outcomes of transcatheter or surgical aortic valve replacement[J].Circ Cardiovasc Interv,2022,15(1):e011375.DOI:10.1161/CIRCINTERVENTIONS.121.011375.